Panorama Therapeutics

Panorama Medicine is a private biotechnology company focused on discovering therapeutics for diseases driven by RNA splicing defects and other transcriptomic abnormalities. The company combines genomics, computational biology, artificial intelligence, and transcriptome-wide small-molecule screening in its proprietary Pan-ACEA platform to identify therapeutic leads. Its work appears centered on repurposed or de-risked small molecules and transcriptome modulation for both rare and common diseases. Publicly described programs include efforts in oncology through modulation of MDM4 splicing and in rare neurologic disease through restoration of SCN1A and STXBP1 transcript expression. In addition to internal drug discovery, the company has indicated interest in licensing and custom screening collaborations.